In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620

Journal of Neuro-Oncology

Volumn 61, Issue 2, 2003, Pages 103-112

  Kurimoto, Masanori ^a   Hirashima, Yutaka ^a   Hamada, Hideo ^a   Kamiyama, Hironaga ^a   Nagai, Shoichi ^a   Hayashi, Nakamasa ^a   Endo, Shunro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Astrocytoma cells; Farnesyltransferase inhibitor; Growth inhibition; Ras

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ANGIOGENESIS INHIBITOR; B 1620; CYTOSTATIC AGENT; PRODRUG; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASSAY; ASTROCYTE; ASTROCYTOMA; BRAIN; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL ANCHORAGE; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INACTIVATION; DRUG MECHANISM; FEMALE; FETUS; HISTOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; ONCOGENE RAS; PHENOTYPE; STAINING; VASCULARIZATION; XENOGRAFT;

ALKYL AND ARYL TRANSFERASES; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL DIVISION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; IMMUNOBLOTTING; IN SITU NICK-END LABELING; ISOQUINOLINES; MICE; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEIN P21(RAS); PRODRUGS; TUMOR CELLS, CULTURED;

EID: 0037284728     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022132201313     Document Type: Article

References (33)

1. Bredel M, Pollack IF: The p21-Ras signal transduction pathway and growth regulation in human high grade gliomas. Brain Res Rev 29: 232-249, 1999
2. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP: Genes for epidermal growth factor receptor, transforming growth factor-alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172, 1991
3. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN: Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86: 131-140, 1990
4. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903, 1987
5. Bollag G, McCormick F: Regulators and effectors of Ras proteins. Annu Rev Cell Biol 7: 601-632, 1991
6. McCormick F: Signal transduction. How receptors turn Ras on. Nature 363: 15-16, 1993
7. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 366: 643-654, 1993
8. Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR, Avruch J: Raf-1 activates MAP kinase-kinase. Nature 358: 417-421, 1992
9. Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras? Biochem Biophys Acta 1333: F51-F71, 1997
10. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE, Oliff A: Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo. J Biol Chem 268: 7617-7620, 1993
11. Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77: 175-178, 1994
12. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC Jr: Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 260: 1937-1942, 1993
13. Kohl NE, Mosser SD, DeSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934-1937, 1993
14. Garcia AM, Rowell C, Ackermann K, Kowalczyk JJ, Lewis MD: Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem 268: 18415-18418, 1993
15. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55: 5310-5314, 1995
16. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55: 5302-5309, 1995
17. Mangues R, Corral T, Kohl NE, Symmans WF, Lu S, Malumbres M, Gibbs JB, Oliff A, Pellicer S: Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 58: 1253-1259, 1998
18. Feldkamp MM, Lau N, Roncari L, Guha A: Isotype-specific Ras. GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 61: 4425-4431, 2001
19. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15: 2755-2765, 1997
20. Arai K, Horie Y, Kurimoto M, Endoh S, Hiraga K, Takaku A: A cell line of human malignant astrocytoma producing autocrine growth factor. In Vitro Cell Dev Biol 27A: 606-614, 1991
21. Kurimoto M, Hirashima Y, Ogiichi T, Hamada H, Kamiyama H, Endo S: Establishment and characterization of a novel malignant astrocytoma cell line derived from a tumor removed in a patient with neurofibromatosis type 1. J Neurosurg 94: 348-349, 2001
22. Mosman T: Rapid colorimetric assay for cellular growth and survival' application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983
23. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88, 1993
24. Kataoka Y, Murley JS, Patel R, Grdina DJ: Cytoprotection by WR-1065, the active form of amifostine, is independent by p53 status in human malignant glioma cell lines. Int J Radiat Biol 76: 633-639, 2000.
25. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedman T, De Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652, 1994
26. Feldkamp MM, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18: 7514-7526, 1999
27. Glass TL, Liu T-J, Yung WKA: Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro-Oncology 2: 151-158, 2000
28. Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM: Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II - Preclinical studies in a nude mouse model. Neurosurgery 45: 1208-1215, 1999
29. Gille H, Downward J: Multiple ras effector pathways contribute to G1 cell cycle progression. J Biol Chem 274: 22033-22040, 1999
30. Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V: Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res 55: 3569-3575, 1995
31. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995
32. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH: Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6: 2318-2325, 2000
33. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bok K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange B, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 97: 3361-3369, 2001